RxDoctor Payments DataLook up a doctor →

Amita Patel, MD

Psychiatry · Dayton, OHNPI 1649265489

Payments from drug & device makers

$2,130,861in general payments, 2019–2025

Across 2,362 payments — averaging $902.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$700K
  • Otsuka America Pharmaceutical, Inc.$461K
  • Teva Pharmaceuticals USA, Inc.$384K
  • Avanir Pharmaceuticals, Inc.$309K
  • Acadia Pharmaceuticals Inc$139K
  • E.r. Squibb & Sons, L.L.C.$112K
  • plus $25K from 16 others

What the payments were for

  • Consulting fees$288,82114%
  • Speaking & faculty fees$1,545,68073%
  • Travel & lodging$249,52412%
  • Food & beverage$46,3952%
  • Education$4410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,130,861 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$98,961
Medicare patients
272
Services billed
1,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine93$630,401
IngrezzaValbenazine Tosylate73$470,874
AustedoDeutetrabenazine44$266,897
RexultiBrexpiprazole87$85,547
NuedextaDextromethorphan Hbr/Quinidine59$74,819
Divalproex Sodium219$12,205
Buspirone Hcl422$11,161
Olanzapine101$7,706
Duloxetine Hcl215$6,606
Mirtazapine259$6,544
Quetiapine Fumarate213$6,125
EquetroCarbamazepine14$5,758
Memantine Hcl110$4,937
Propranolol Hcl118$4,884
Donepezil Hcl210$4,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$384,357$897,298137 claims
Neurocrine Biosciences, Inc.Ingrezza$700,183$470,87473 claims
Otsuka America Pharmaceutical, Inc.Rexulti$460,959$85,54787 claims
Avanir Pharmaceuticals, Inc.Nuedexta$309,459$74,81959 claims
Lilly USA, LLCOlanzapine$74$7,706101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →